L. reuteri ATCC PTA 6475.
The "testosterone probiotic." Rodent studies show impressive hormone effects. A named strain that ferments sugars to lactate and acetate and makes reuterin from glycerol. Human work has measured gut, gum and bone density readings.
Reviewed March 2026
- Category
- Probiotic
- Also filed under
- TestosteroneBone healthSkin/hair
What L. reuteri ATCC PTA 6475 is, and what it does.
- Does it work
- Suits older adults and women in the years after their cycles end who want the strain with a year-long bone density trial behind it, plus gut and gum routines.
- How much to take
- No dose figure is on record for this strain. Labels count live cells per serving, and the ATCC PTA 6475 code is what ties a serving to the research.
- Time to feel it
- Nobody has measured a felt onset for this strain. Gut measures shift over two to four weeks, and the bone density trial ran a full twelve months.
- The first dose
- Day one is quiet. Live cells are arriving and starting to ferment, and a little extra gas in the first days is the common report.
- With regular use
- Gut and gum measures shift across four to eight weeks. The bone density work ran a full year of daily use, and the cells clear once dosing stops.
- How well tolerated
- Well tolerated, with mild gas in the first days the usual report. Anyone severely immunocompromised or with a central venous catheter should check first.
- How it feels
- There's no immediate sensation. People describe steadier digestion after a few weeks, while the bone and hormone work is measured rather than felt.
- The overlooked benefit
- The testosterone headline comes from rodents. What has been measured in people is bone mineral density in older women, across a year of daily use.
1,000,000,000 to 10,000,000,000 CFU a day is where L. reuteri ATCC PTA 6475 works.
Source: ISAPP consensus statement 2019 + Ford 2014 meta-analysis
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
L. reuteri ATCC PTA 6475 has emerging evidence. Based on 178+ studies.
- Bone mineral density in older womenRandomised trial
- Reproductive hormone measures in rodentsAnimal study
- Inflammatory signalling in intestinal cellsIn vitro study
- Gum and oral bacterial measuresRandomised trial
- Antimicrobial activity through reuterinIn vitro study
Questions people ask about L. reuteri ATCC PTA 6475.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- How long until I notice something?
- GI effects can show within days. Immune and mood benefits take 4-8 weeks of consistent use.
- Do I need to refrigerate it?
- Depends on the brand. Shelf-stable formulas exist and work fine. But if it says refrigerate, do it. Dead bacteria don't help anyone.
- Should I take it with food?
- With or right before a meal, ideally. The food buffers stomach acid and gives the bacteria a better chance of surviving the trip down.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Galactooligosaccharides pass undigested to the colon, where lactobacilli ferment them to lactate and short-chain fatty acids. A young child formula pairing Limosilactobacillus reuteri with GOS was studied for gut microbiome composition and growth measures, so the two have been given together rather than only inferred. The microbiome readouts are compositional markers, not clinical outcomes.
Inulin is a fructan that human enzymes cannot hydrolyse, so it reaches the colon intact and is fermented by resident lactic acid bacteria. Supplying fermentable substrate alongside a live strain gives that strain something to grow on. This is substrate provision, not a demonstrated clinical additive effect.
Short-chain fructooligosaccharides are fermented preferentially by lactobacilli and bifidobacteria in the proximal colon. Formulators pair them with lactic acid bacteria for that reason. The pairing is formulation convention supported by fermentation biochemistry rather than by a trial of this specific strain.
Vitamin D governs intestinal calcium absorption, which sets how much mineral is available for normal bone turnover. L. reuteri ATCC PTA 6475 has been studied for its effect on bone mineral density in early postmenopausal women, a marker of skeletal mineral handling. Any bone-related contribution of the strain still depends on adequate calcium and vitamin D status.
Calcium is the substrate for hydroxyapatite and no microbial signal can compensate for an inadequate intake. Colonic fermentation lowers luminal pH, which keeps calcium in a soluble ionised state available for passive absorption. That mechanism is established for fermentative organisms generally.
Menaquinone-7 is the cofactor for gamma-glutamyl carboxylase, the enzyme that carboxylates osteocalcin so it can bind calcium into bone matrix. It sits downstream of mineral supply rather than competing with it. Pairing addresses a different step in normal bone mineral handling than a live strain does.
Limosilactobacillus reuteri is one of the few lactobacilli carrying the cobalamin biosynthesis operon, and it uses a B12-dependent diol dehydratase to convert glycerol to reuterin. Colonic synthesis sits distal to the ileal absorption site, so microbial production is not a reliable dietary source. Regard the relationship as biochemical rather than as a way to raise B12 status.
Several lactobacilli synthesise folate in the colon and a systematic review has mapped the two-way relationship between dietary folate and enteric microbial populations. Colonic folate is absorbed by a proton-coupled transporter, so it is not simply discarded. The strain-specific yield varies widely and is not established for this strain.
An oral rehydration solution enriched with both L. reuteri DSM 17938 and zinc has been studied in children for gastrointestinal recovery measures. That trial used a different strain from ATCC PTA 6475, so it supports the pairing concept rather than this strain. Zinc contributes independently to normal intestinal barrier function.
Saccharomyces boulardii is a yeast, so it occupies a different niche from a lactic acid bacterium and is unaffected by most antibacterial pressures. Multi-organism blends are built on that non-overlap. The combination has not been characterised for this specific strain pairing.
Multi-strain blends combine species with different fermentation profiles and adhesion patterns to widen colonic coverage. L. plantarum is obligately heterofermentative in part and tolerates a broad pH range. Strains within a blend can also compete for the same substrate, so more strains is not automatically more effect.
Bifidobacteria ferment oligosaccharides to acetate and lactate, which lactobacilli and butyrate producers use in cross-feeding chains. That metabolic hand-off is well described in colonic ecology. Whether it changes any measured outcome when the two are taken together has not been established for this strain.
Resistant starch escapes small-intestinal amylase and is fermented in the distal colon, further along than inulin or FOS reach. Pairing a live strain with a slowly fermented substrate extends fermentation deeper into the bowel. The effect is on substrate availability, not on strain survival through the stomach.
Lactoferrin binds free iron tightly, which restricts iron available to iron-requiring enteric organisms. Lactobacilli are unusual in having little or no iron requirement, so they are comparatively unaffected by that sequestration. The selective pressure is a plausible mechanism rather than a measured combination effect.
Bovine colostrum supplies secretory immunoglobulins and oligosaccharides that reach the colon largely intact. The oligosaccharide fraction is fermentable by lactobacilli. This is substrate and barrier support alongside a live organism, not a tested pairing for this strain.
Nothing specific on file for L. reuteri ATCC PTA 6475. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What L. reuteri ATCC PTA 6475 actually does.
Limosilactobacillus reuteri is an obligately heterofermentative lactic acid bacterium: it ferments hexoses through the phosphoketolase pathway to lactate, acetate, ethanol and carbon dioxide rather than to lactate alone.
The organism carries a vitamin B12-dependent glycerol dehydratase that converts glycerol to 3-hydroxypropionaldehyde, the compound known as reuterin, which is the basis of its antimicrobial signature in the gut lumen.
Lactate and acetate produced by fermentation lower luminal pH, which keeps minerals such as calcium in a soluble ionised form and disfavours acid-sensitive organisms.
Probiotic effects are strain-specific, not species-specific: ATCC PTA 6475, DSM 17938 and ATCC PTA 4659 differ in genome content and in the metabolites they produce, so evidence for one does not transfer to another.
Getting L. reuteri ATCC PTA 6475 from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A twelve-month randomised comparison of Limosilactobacillus reuteri 6475 against placebo reporting change in tibia bone mineral density, which is a densitometric marker rather than a clinical outcome.Randomised trial. Gregori et al., 2024 (JAMA Network Open). PMID 38865129 ↗
- One year of Lactobacillus reuteri ATCC PTA 6475 was assessed against placebo for shifts in gut microbiota composition in older adults; the endpoints are compositional markers.Randomised trial. Li et al., 2022 (npj Biofilms and Microbiomes). PMID 36261538 ↗
- A systematic review and meta-analysis pooling randomised controlled trials of Lactobacillus supplementation across mixed endpoints and mixed strains.Meta-analysis. Azam et al., 2025 (MicrobiologyOpen). PMID 41327607 ↗
- A young child formula containing Limosilactobacillus reuteri with galactooligosaccharides was compared for gut microbiome composition alongside bone and muscle growth measures.Randomised trial. Bonnet et al., 2025 (Nature Communications). PMID 41387706 ↗
- A review of Limosilactobacillus reuteri as a gut commensal, describing strain-dependent and context-dependent effects on normal immune signalling.Narrative review. Lee et al., 2025 (Gut Microbes). PMID 39825615 ↗
- Genomic and phenotypic characterisation with clinical tolerability data for Limosilactobacillus reuteri ATCC PTA 4659, a sibling strain rather than 6475.Narrative review. Sendelius et al., 2023 (Journal of Industrial Microbiology and Biotechnology). PMID 37974056 ↗
- Short-course acid-suppressing therapy with or without high-dose L. reuteri was compared for how far the gut microbiome shifted and recovered; the readout is compositional.Randomised trial. Bibbo et al., 2025 (Helicobacter). PMID 40993967 ↗
- Metagenomic sequencing tracked gut microbiota composition through a simplified antimicrobial regimen; the endpoints are microbial community markers.Randomised trial. Dore et al., 2022 (Nutrients). PMID 35889746 ↗
- An oral rehydration solution enriched with L. reuteri DSM 17938 plus zinc was compared with standard rehydration in children; the strain studied is DSM 17938, not ATCC PTA 6475.Randomised trial. Maragkoudaki et al., 2018 (Nutrients). PMID 30200394 ↗
- Perinatal Limosilactobacillus reuteri produced sex-specific differences in social behaviour, gene expression and gut measures in rodents; no human inference follows.Animal study. Siegler Lathrop et al., 2025 (Journal of Neurochemistry). PMID 40827476 ↗
- A microbial lysate upregulated host oxytocin in a rodent model, one of the mechanistic threads behind interest in this genus.Animal study. Varian et al., 2017 (Brain, Behavior, and Immunity). PMID 27825953 ↗
- A review of the roles of Limosilactobacillus reuteri and related species, summarising proposed mechanisms across the gut and beyond.Narrative review. Li et al., 2026 (International Journal of Molecular Sciences). PMID 41683964 ↗
- A systematic review of probiotic supplementation trials in children that names L. reuteri among the strains used; strains and endpoints are heterogeneous.Systematic review. Chan et al., 2026 (Nutrients). PMID 41978177 ↗
These are the studies our verdict leans on, chosen from the 13 we read for L. reuteri ATCC PTA 6475. The full linked list is below.
The studies, linked.
3 sources behind our L. reuteri ATCC PTA 6475 verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialRandomized Clinical Trial on the Safety and Efficacy of L. Reuteri DSM 17938 and L. Reuteri ATCC PTA 6475 in the Treatment of Moderate to Severe Irritable Bowel Syndrome in Adults. Version 1.0, CSUB 0137, 27Jun2017ClinicalTrials.gov ↗NA · 140 participants · Completed
- Clinical trialTwice-a-day PPI, Tetracycline, Metronidazolequadruple Therapy With Pylera® or Lactobacillus Reuteri for Treatment naïve or for Retreatment of H. Pylori: Two Randomized Pilot StudiesClinicalTrials.gov ↗NA · 99 participants · Terminated
- Clinical trialEffect of Dietary Supplementation With L. Reuteri ProGastria in H. Pylori-infected Adult Subjects Treated Only With Proton Pump InhibitorsClinicalTrials.gov ↗NA · 56 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.